A new trial phase 1 trial is investigating the combination of 177Lu-PSMA-617 (Pluvicto) with darolutamide in high-risk localized prostate cancer. Both agents are already established in prostate cancer care, but using them together before surgery is a novel way to intensify treatment in patients whose disease is still potentially curable. Its main idea is simple: […]
177Lu‑PSMA‑VG01 is a next‑generation, small‑molecule PSMA‑targeting radiopharmaceutical designed to refine what 177Lu‑PSMA‑617 (Pluvicto) has already achieved. It uses a high‑affinity ligand to deliver the beta‑emitter lutetium‑177 directly to PSMA‑expressing tumor cells, aiming for greater tumor dosing with less exposure of healthy tissue. A new phase 1 trial is testing its dosimetry and side effects on […]
Zanzalintinib is being tested after Pluvicto (177Lu-PSMA-617) in metastatic castration‑resistant prostate cancer (mCRPC) because it targets several escape routes tumors use once they have survived PSMA‑directed radioligand therapy and prolonged AR pathway blockade. Pluvicto delivers beta radiation to PSMA‑expressing cells, inducing DNA damage and tumor cell death, but progression still occurs and is often driven […]
A pivotal Phase 3 trial called VECTRA-01 has launched to evaluate AZD2265 (²²⁵Ac-PSMA-I&T), an alpha-emitting radioligand therapy targeting PSMA-positive metastatic castration-resistant prostate cancer. The study began in May 2026, enrolling approximately 670 participants across 90 global sites, with recruitment currently active at select locations. The trial’s primary objective is to demonstrate superiority over standard of […]
Results from the PSMAddition trial were published in a phase 3 setting and showed several clear numbers worth noting. The trial compared standard double hormone-based treatment alone (ADT + ARPI) versus the same treatment plus a PSMA-targeted radioligand therapy (Pluvicto), in men with metastatic hormone-sensitive prostate cancer.The biggest headline was a 58% lower risk of […]
Metastatic castration-resistant prostate cancer (mCRPC) remains one of the most challenging stages of prostate cancer, marked by poor prognosis and limited durable treatment options. The radioligand therapy 177Lu-PSMA-617 (Pluvicto) has emerged as a significant advance, demonstrating an overall survival benefit in selected patients. However, clinical responses vary widely, highlighting an urgent need for biomarkers that […]
The PRINCE trial has delivered final results showing promise for treating metastatic castration-resistant prostate cancer (mCRPC) with the combination of 177Lu-PSMA-617 (Pluvicto) and pembrolizumab. Published in The Lancet Oncology on April 1, 2026 , this single-arm, phase 1b/2 trial enrolled 37 heavily pretreated men (median age 72, 73% prior docetaxel, 100% prior AR inhibitors) who […]
The UPLIFT trial is a phase 1/2 study testing a new combo for metastatic castrate-resistant prostate cancer. Researchers at the University of California, San Francisco, designed this trial to boost the power of 177Lu-PSMA-617, a targeted radiation drug called a radioligand therapy. That drug latches onto PSMA, a protein stamped all over prostate cancer cells, […]
Genomic alterations like TP53, PTEN, and RB1 mutations are prevalent in metastatic castration-resistant prostate cancer (mCRPC), yet their impact on response to 177Lu-PSMA-617 (LuPSMA, Pluvicto) radioligand therapy remains underexplored. A recent retrospective study published in the Journal of Nuclear Medicine analyzed 72 mCRPC patients treated with at least one cycle of LuPSMA between October 2022 […]
The ANDROMEDA phase 2 trial represents an advancement in managing recurrent oligometastatic prostate cancer by directly pitting alpha-emitting 225Ac-PSMA-617 against the established beta-emitting 177Lu-PSMA-617 (Pluvicto), both combined with stereotactic body radiotherapy (SBRT). This head-to-head comparison stems from the need to address limitations in current therapies for patients whose cancer returns in 1-5 detectable spots on […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy